During the past grant cycle, using a variety of rat models, we have proven that Rab38 is responsible for the quantitative trait locus (QTL) named Rf-2, identified and validated that Sorcs1 is responsible for the QTL named Rf-1, and have identified that Shroom3 causes changes in glomerular permeability. We have made considerable strides towards cloning by position two other QTL, Rf-3 and Rf-4. In collaboration with the Chronic Kidney Disease Genetics (CKDGen) Consortium, we found that SORCS1 and SHROOM3 are significantly associated with renal disease in humans, demonstrating that this work has clinical relevance. Our long-term goal is to define the genetic architecture of end stage renal disease (ESRD). Our data suggests that a defect in both the glomerular permeability and protein trafficking in the proximal tubules is required for proteinuria, which is now our centrl hypothesis. The proposed Specific Aims are to 1) test a collection of human sequence variants of SHROOM3 predicted to be dysfunctional;2) identify the genes/genomic elements underlying the QTL Rf-3 (interval size 1.81 Mb) and QTL Rf-4 (interval size 0.9 Mb) participating in glomerular permeability, which is thought to initiate proteinuria;and 3) test the central hypothesis that dysfunction in both glomerular permeability and protein trafficking in the proximal tubules are participating together in the development of proteinuria. Testing this central hypothesis requires the use of whole animals and cannot be done in human. Our genetic/genomic infrastructure for this proposal includes: complete genomic sequence of parental strains, NextGen sequencing tools including bioinformatic analysis, """"""""narrow"""""""" congenic strains, three identified causative genes, as well as detailed physiological characterization creating an ideal platform for discovering important new genes and testing this new central hypothesis. We will study human variants of SHROOM3 in HEK293 cells, zebrafish and humanized sensitized FHH rat model for CKD. Specifically, Aim 1 tests a collection of human variants for renal disease and demonstrates how model systems can be used to follow-up genes nominated by many genome-wide association studies (GWAS). Our collaboration with the CKDGen enables us to test if the genes identified for Rf-3 and Rf-4 contribute to human disease;thereby, providing knowledge about the disease process in humans. The rationale for the proposed research is the test of human variation in SHROOM3, identification of new genes, and a new hypothesis which will provide new insights into this disease process and could identify new targets for future treatment of renal disease with a rising incidence and limited effective treatments.
Specific aims 1 -3 are expected to reveal the knowledge about how mutated SHROOM3 functions and identify two new genes, which will either link to known pathways or unmask new ones. We will also determine if two hits (one in the glomeruli and one in proximal tubules) are involved.
Each aim of this proposal will provide fundamental advances toward defining the genetic architecture of proteinuria which is often the precursor of ESRD.
End stage renal disease (ESRD) has a survival rate lower than breast or prostate cancer and an increasing prevalence despite improved treatments for hypertension and diabetes. Data from epidemiological studies, genome wide associations studies (GWAS) and animal models (including many from our lab) have shown that genetic susceptibility plays a critical role in the disease process of ESRD. This grant is designed find two new genes involved in glomerular function, test sequence variants identified in the human SHROOM3 gene, and to study the genetic architecture of proteinuria, a precursor of ESRD.
|Prokop, Jeremy W; Yeo, Nan Cher; Ottmann, Christian et al. (2018) Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD. J Am Soc Nephrol 29:1525-1535|
|Prokop, Jeremy W; Lazar, Jozef; Crapitto, Gabrielle et al. (2017) Molecular modeling in the age of clinical genomics, the enterprise of the next generation. J Mol Model 23:75|
|Miller, Bradley; Palygin, Oleg; Rufanova, Victoriya A et al. (2016) p66Shc regulates renal vascular tone in hypertension-induced nephropathy. J Clin Invest 126:2533-46|
|Teumer, Alexander; Tin, Adrienne; Sorice, Rossella et al. (2016) Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. Diabetes 65:803-17|
|Yeo, Nan Cher; O'Meara, Caitlin C; Bonomo, Jason A et al. (2015) Shroom3 contributes to the maintenance of the glomerular filtration barrier integrity. Genome Res 25:57-65|
|Prisco, Sasha Z; Prokop, Jeremy W; Sarkis, Allison B et al. (2014) Refined mapping of a hypertension susceptibility locus on rat chromosome 12. Hypertension 64:883-90|
|Atanur, Santosh S; Diaz, Ana Garcia; Maratou, Klio et al. (2013) Genome sequencing reveals loci under artificial selection that underlie disease phenotypes in the laboratory rat. Cell 154:691-703|
|Katter, Katharina; Geurts, Aron M; Hoffmann, Orsolya et al. (2013) Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits. FASEB J 27:930-41|
|Lazar, Jozef; O'Meara, Caitlin C; Sarkis, Allison B et al. (2013) SORCS1 contributes to the development of renal disease in rats and humans. Physiol Genomics 45:720-8|
|Rangel-Filho, Artur; Lazar, Jozef; Moreno, Carol et al. (2013) Rab38 modulates proteinuria in model of hypertension-associated renal disease. J Am Soc Nephrol 24:283-92|
Showing the most recent 10 out of 22 publications